Category Archives: Dr. Pravin Dugel

Pravin U. Dugel, MD: Opthea Meets Primary Endpoint in Phase 2b Study of OPT-302 in Wet AMD

OPT-302 Combination Therapy Demonstrated Superiority in Visual Acuity over Lucentis® The primary outcome achieved: OPT-302 + Lucentis (ranibizumab) combination therapy demonstrated a statistically significant vision benefit compared to Lucentis in wet AMD patients at 24 weeks in a trial of 366 patients Intravitreal OPT-302 combination therapy was well tolerated with a safety profile similar to… Read More »


Pravin U. Dugel MD: 1,800 Seconds™ in Advances in the Management of Age-Related Macular Degeneration

EARN CREDIT NOW Course Director: Pravin U. Dugel, MD Release Date: March 31, 2019 Expiration Date: March 31, 2020 Credits Available: Physicians – maximum of 0.5 AMA PRA Category 1 Credits™ Jointly provided by Postgraduate Institute for Medicine and Catamount Medical Education Supported by an independent educational grant from Novartis Pharmaceuticals Corporation Release Date: March… Read More »


Dr. Pravin U. Dugel: Oxurion NV Reports Positive Topline Phase 1 Results with THR-149

Oxurion NV Reports Positive Topline Phase 1 Results with THR-149, a novel, potent plasma kallikrein inhibitor for the treatment of DME Topline data show that THR-149 is well-tolerated and safe. No dose-limiting toxicities or drug-related serious adverse events reported. Rapid onset of action starting at Day 1 with increasing average improvement in Best Corrected Visual… Read More »


Dr. Pravin U. Dugel Chairs Retina World Congress Unplugged

RWC Unplugged offers participants a unique opportunity to learn, share and discuss controversial topics in retina with a large group of industry experts and clinical leaders. With no scripts or industry commercials, this event evokes deep discussions moderated by KOLs, who encourage attendees to challenge their perspectives in lively, no-holds-barred discussions, with live polling on… Read More »


Dr. Pravin U. Dugel – First Patients in Arizona Receive Experimental Stem Cell Treatment for Eye Disease

PHOENIX (Feb. 11, 2019)– Retinal Consultants of Arizona & the Retinal Research Institute – one of the nation’s leading retina & vitreous clinical research and patient treatment facilities – is proud to announce that Dr. Pravin U. Dugel has conducted the first stem cell therapy treatment for patients with retinitis pigmentosa (RP) in Arizona. The… Read More »


Dr. Pravin U. Dugel: Two-year data for Novartis brolucizumab reaffirm superiority versus aflibercept in reducing retinal fluid in patients with nAMD

October 27, 2018 10:09 ET | Source:  Novartis International AG Year two results consistent with previously announced key secondary endpoint data on retinal fluid (IRF and/or SRF) showing superior reductions versus aflibercept Superior reductions in central subfield thickness demonstrated at year one were reaffirmed at year two with brolucizumab 6 mg versus aflibercept Robust visual gains shown in… Read More »


EUROTIMES – Innovation in Retina Surgery – Dr. Pravin U. Dugel Interview

INNOVATION IN RETINA SURGERY: Technological innovation is crucial to the continued improvement 
of vitreoretinal surgery. Leigh Spielberg Posted: EUROTIMES – Thursday, March 1, 2018 Technological innovation is crucial to the continued improvement of vitreoretinal surgery. This was abundantly apparent during the RetinaTech Bio-Engineering Session during the 17th EURETINA Congress in Barcelona, Spain. Subtitled “Where Surgery… Read More »